Table 2 Comparison of tumour growth rates
From: Growth of breast cancer recurrences assessed by consecutive MRI
Characteristic | n | Growth rate b (10-3 days-1) | Actual doubling time DTact (days) | P |
|---|---|---|---|---|
Age at detectionL | Â | Â | Â | Â |
   < 59 y. (median) | 18 | 2.01 (-1.41 - 5.77) | 341 (-685 - 785) | 0.79 |
   >= 59 y. | 19 | 2.21 (-0.12 - 5.79) | 343 (-6797 - 4470) |  |
Menopausal status | Â | Â | Â | Â |
   Pre- | 7 | 2.73 (1.25 - 3.98) | 293 (193 - 651) |  |
   Post-, with hormone therapy | 3 | -0.12 (-1.41 - 2.18) | -685 (-6797 - 343) | 0.14 |
   Post-, without HT | 27 | 2.22 (0.18 - 5.79) | 344 (129 - 4470) |  |
Personal history | Â | Â | Â | Â |
   No previous breast cancer | 20 | 2.09 (-1.41 - 3.98) | 284 (-6797 - 4470) |  |
   Ipsilateral recurrence | 7 | 1.38 (1.10 - 2.22) | 581 (344 - 710) | 0.004 |
   Contralateral recurrence | 10 | 3.56 (1.65 - 5.79) | 221 (129 - 481) |  |
Contralateral recurrence | Â | Â | Â | Â |
   No | 27 | 1.69 (-1.41 - 3.98) | 390 (-6797 - 4470) | 0.001 |
   Yes | 10 | 3.56 (1.65 - 5.79) | 221 (129 - 481) |  |
Treatment of primary breast cancer | ||||
Surgery | Â | Â | Â | Â |
   Breast-conserving surgery | 15 | 2.12 (1.10 - 5.77) | 355 (129 - 710) | 0.19 |
   Mastectomy | 2 | 4.02 (2.26 - 5.79) | 237 (130 - 344) |  |
Radiotherapy | Â | Â | Â | Â |
   No | 1 | 5.79 (5.79 - 5.79) | 130 (130 - 130) | 0.10 |
   Yes | 16 | 2.17 (1.10 - 5.77) | 349 (129 - 710) |  |
Chemotherapy | Â | Â | Â | Â |
   No | 9 | 2.02 (1.10 - 5.79) | 390 (129 - 710) | 0.71 |
   Yes | 8 | 2.24 (1.19 - 5.76) | 344 (141 - 660) |  |
Hormonal therapy | Â | Â | Â | Â |
   No | 11 | 2.26 (1.10 - 5.79) | 344 (129 - 710) | 0.90 |
   Yes | 4 | 2.51 (1.19 - 5.76) | 335 (141 - 660) |  |
Location of cancer | Â | Â | Â | Â |
   Inner | 8 | 2.09 (1.10 - 5.79) | 376 (129 - 785) |  |
   Central | 5 | 2.89 (1.38 - 3.33) | 293 (245 - 604) | 0.70 |
   Outer | 24 | 2.17 (-1.41 - 5.76) | 330 (-6797 - 4470) |  |
Histology | Â | Â | Â | Â |
   Invasive carcinoma | 33 | 2.21 (-0.12 - 5.79) | 343 (-6797 - 4470) | 0.17 |
   In situ carcinoma | 4 | 0.75 (-1.41 - 5.76) | 401 (-685 - 2643) |  |
Grade | Â | Â | Â | Â |
   SBR 1 | 13 | 2.00 (0.18 - 3.82) | 409 (192 - 4470) |  |
   SBR 2 | 14 | 2.59 (-0.12 - 5.79) | 273 (-6797 - 710) | 0.17 |
   SBR 3 | 6 | 2.81 (1.10 - 3.35) | 284 (234 - 785) |  |
Tumour initial volume | Â | Â | Â | Â |
   < 139 mm3 (median) | 18 | 2.73 (0.91 - 5.79) | 274 (129 - 817) | 0.04 |
   ≥ 139 mm3 | 19 | 1.52 (-1.41 - 5.76) | 399 (-6797 - 4470) |  |
Oestrogen receptors | Â | Â | Â | Â |
   < 90% (median) | 15 | 2.22 (-0.12 - 5.77) | 293 (-6797 - 4470) | 0.75 |
   ≥ 90% | 17 | 2.12 (0.91 - 5.79) | 355 (130 - 817) |  |
Progesterone receptors | Â | Â | Â | Â |
   < 35% (median) | 16 | 1.95 (-0.12 - 3.84) | 318 (-6797 - 785) | 0.44 |
   >= 35% | 16 | 2.22 (0.18 - 5.79) | 343 (129 - 4470) |  |
Ki67 | Â | Â | Â | Â |
   < 7.5% (median) | 13 | 2.18 (-0.12 - 5.77) | 265 (-6797 - 4470) | 0.67 |
   ≥ 7.5% | 13 | 2.26 (1.10 - 5.79) | 344 (130 - 710) |  |
Mitotic count | Â | Â | Â | Â |
   < 3.5 (median) | 16 | 2.01 (0.18 - 3.98) | 399 (192 - 4470) | 0.17 |
   ≥ 3.5 | 16 | 2.81 (-0.12 - 5.79) | 284 (-6797 - 785) |  |